Overview

• Capivasertib, also known as Truqap, has been approved by NICE for NHS use in England and Wales, benefiting up to 3,000 women annually.
• The drug targets hormone receptor-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN mutations, found in about half of such cases.
• Clinical trials demonstrated that capivasertib, combined with fulvestrant, extends progression-free survival by an average of 4.2 months compared to standard treatment.
• The approval follows decades of collaborative research by the Institute of Cancer Research, AstraZeneca, and other partners, underscoring the importance of targeted therapies.
• Experts emphasize the need for prompt genetic testing to identify eligible patients and ensure timely access to the treatment.